Researchers at UC Davis Cancer Center report a significant extension of survival in advanced lung cancer patients treated with bortezomib plus standard care. The median overall survival was 11 months, with one-year survival at 46%, offering promising results for this patient population.
A five-year update from the IRIS Study Group shows excellent results for people with Chronic Myelogenous Leukemia (CML) treated with Gleevec, a targeted cancer therapy. Overall survival rates reach 89% at five years, with fewer than 1% of patients progressing to accelerated or blast crisis phases.
A study found that annual rates of hip fracture among Swiss female nursing home residents decreased by 1.3% per year during the 1990s. This decrease was linked to improved prescription of calcium and vitamin D, as well as enhanced preventative care regarding risk factors for falls.
Early breast cancer patients switching from tamoxifen to Aromasin experience a 17% lower chance of dying and a 25% lower risk of breast cancer recurrence. The study's findings also suggest long-term safety benefits, with no clinically meaningful changes in the side effect profile.
A study of 57 women with metastatic breast cancer found that low-income African-American women experienced higher levels of symptom distress and lower quality of life compared to other racial and economic groups. The researchers emphasize the need for tailored care approaches to improve outcomes for these patients.
Researchers used gene therapy to treat ovarian cancer in a mouse model, achieving complete inhibition of tumor growth in some mice and significant inhibition in others. The treatment offers a promising alternative to harsh current treatments for this deadly disease.
Researchers developed gene therapy using manganese superoxide dismutase to protect mice from radiation damage. The treatment showed no changes in body weight, little bone-marrow damage, and longer lifespan in mice exposed to varying doses of whole-body radiation.
Research suggests strontium ranelate strengthens bone architecture for at least five years, reducing fracture risk. Bisphosphonates remain effective for extended periods, but may pose risks to young patients with osteoporosis.
A study led by Michael C. Heinrich, M.D., found that patients with gastrointestinal stromal tumor (GIST) responded differently to Sunitinib depending on their tumor's genetic abnormality. The research highlights the importance of personalized medicine in cancer treatment.
Studies reveal that age-related changes in bone geometry and architecture can lead to increased fracture risk. Researchers found that older women experience a decrease in dense spongy tissue and an increase in cortical bone thickness, but not overall bone density.
A new study confirms that, despite an increase in hospice care, many terminally ill cancer patients continue to receive aggressive treatment in the last days of life. The study found that while hospice use increased steadily over time, it was often not used for symptom relief and building relationships.